Granting/withdrawal/surrender/cancellation/suspension of key licenses/ regulatory approvals

25th September 2026 IOLCP/CGC/2026 National Stock Exchange of India Ltd BSE Limited Exchange Plaza, Plot no. C/1, G Block, Phiroze Jeejeebhoy Towers, Bandra-Kurla Complex, Bandra (E) Dalal Street Mumbai - 400 051 Mumbai – 400 001 Security Symbol: IOLCP Security Code: 524164 Subject: Grant of Certificate of Suitability (CEP) for Fenofibrate - Process II Dear Sir/Madam, Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are pleased to inform you that the European Directorate for the Quality of Medicines & HealthCare (EDQM) has granted a Certificate of Suitability (CEP) on 24th September 2026 for the Company's Active Pharmaceutical Ingredient (API) product “FENOFIBRATE – Process II”. The aforesaid CEP is in addition to the existing valid CEP held by the Company for “Fenofibrate”. Process II has been developed by the Company to cater the specific process and requirements of its customers. The grant of the CEP further strengthens the Company's regulatory portfolio and supports its ability to cater the regulated markets for Fenofibrate. Details required under abovesaid SEBI Master Circular is annexed herewith as “Annexure -1”. This information will also be accessible on the Company’s website: www.iolcp.com. You are requested to take the above information on record. Thanking You, Yours faithfully, for IOL Chemicals and Pharmaceuticals Limited Abhay Raj Singh Sr. Vice President & Company Secretary Annexure -1 Details required under Regulation 30 of the SEBI Listing Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated 30th January 2026, is annexed herewith Particulars Details a) Name of the regulatory or European Directorate for the Quality of Medicines & HealthCare licensing authority (EDQM) Certificate of Suitability (CEP) for “FENOFIBRATE - Process II”. b) Brief details of the This is in addition to the existing CEP held by the Company for approval/license obtained “FENOFIBRATE”. The approval strength the Company's regulatory compliance and c) Impact/relevance of such facilitates the supply of FENOFIBRATE – Process II in regulated approval/license to the listed entity markets. d) Withdrawal/cancellation or Not applicable. suspension of the approval/license The CEP is valid from 24 September 2026, subject to continued e) Period for which such compliance with the applicable requirements and conditions of the approval/license is/was valid EDQM f) Subsequent actual Not applicable. impact/corrective actions